Skip to main content
Friday, November 13, 2026Nov 13

Biden boosts US vaccine stockpile as world waits

President Joe Biden leaves an event with Johnson and Johnson Chairman and CEO Alex Gorsky, and Merck Chairman and CEO Kenneth Frazier in the South Court Auditorium in the Eisenhower Executive Office Building on the White House Campus, Wednesday, March 10, 2021, in Washington. (AP Photo/Andrew Harnik)
President Joe Biden leaves an event with Johnson and Johnson Chairman and CEO Alex Gorsky, and Merck Chairman and CEO Kenneth Frazier in the South Court Auditorium in the Eisenhower Executive Office Building on the White House Campus, Wednesday, March 10, 2021, in Washington. (AP Photo/Andrew Harnik) President Joe Biden leaves an event with Johnson and Johnson Chairman and CEO Alex Gorsky, and Merck Chairman and CEO Kenneth Frazier in the South Court Auditorium in the Eisenhower Executive Office Building on the White House Campus, Wednesday, March 10, 2021, in Washington. (AP Photo/Andrew Harnik)

WASHINGTON (AP) – President Joe Biden has directed his administration to order another 100 million doses of the Johnson & Johnson coronavirus vaccine, growing a likely U.S. surplus of doses later this year while much of the rest of the world struggles with deep shortages.

Even before Wednesday’s order, the U.S. was to have enough approved vaccine delivered by mid-May to cover every adult and enough for 400 million people total by the end of July. Enough doses to cover 200 million more people are on order should vaccines from AstraZeneca and Novavax receive approval from the Food and Drug Administration. The new J&J doses, which would cover another 100 million people, are expected to be delivered in the latter half of the year.

White House aides said Biden’s first priority is ensuring that Americans are vaccinated before considering distributing doses elsewhere.

“We want to be oversupplied and overprepared,” White House press secretary Jen Psaki said Wednesday, saying Biden wanted contingencies in the event of any unforeseen issues with the existing production timeline.

“We still don’t know which vaccine will be most effective on kids,” she added. “We still don’t know the impact of variants or the need for booster shots. And these doses can be used for booster shots as well as needed. Obviously that’s still being studied by the FDA but again we want to be over-prepared as I noted earlier.”